CAPLIN POINT LAB LTD. Fair Value
CAPLIPOINT · Healthcare · Current price ₹2,715.7
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹996 | 21% ROE fading to 12% over ~20 yrs, on ₹472 book |
| Relative P/E | ₹2,558 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹947 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,505 | Street consensus 12-month target price |
Is CAPLIN POINT LAB LTD. undervalued?
DocStoX estimates the fair value of CAPLIN POINT LAB LTD. at ₹1,621 per share, versus the current market price of ₹2,716. That puts the stock about -40.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹996), Relative P/E (₹2,558), Graham floor (₹947), Analyst target (₹2,505). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹947 (bear) to ₹1,621 (base) to ₹2,558 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on CAPLIN POINT LAB LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.